A prospective cohort study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)
- Conditions
- ovel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003108
- Lead Sponsor
- Hubei Provincial Hospital of TCM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) Corresponding to diagnosis standards of convalescence of COVID-19 mentioned above;
(2) Imaging manifestations Fibrous cable-like shadow (patchy) ground glass changes in the lungs,honeycomb sign,reticular changes, increased bronchovascular shadows, pleural effusion,nodular change, any one or more of the above;
(3) Aged 18-65 years;
(4) Signing of informed consent.
1. With other serious primary pulmonary diseases (such as active pulmonary tuberculosis, pneumothorax, pleural effusion, pulmonary embolism and neuromuscular diseases affecting respiratory and motor function);
2. Severe primary diseases, belong to heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract, may affect the patients' participation in the study or the outcome of the study;
3. A family history of mental illness or a history of mental illness;
4. Allergic constitution or known drug allergy;
5. Pregnant or lactating women and those with recent pregnancy plans;
6. Bedridden for various reasons.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CT Scan-Chest;
- Secondary Outcome Measures
Name Time Method mMRC;The reactivation rate of COVID-19;ST. George's Respiratory Questionnaire;Brog scale;Borg Scale;TCM symptom scale;